Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), is celebrating the official opening of the Iovance Cell Therapy Center (iCTC). The iCTC, located at the Philadelphia Navy Yard, is the first centralized, scalable, state-of-the-art manufacturing facility dedicated to producing TIL cell therapies for patients with
PIDC and University City District’s West Philadelphia Skills Initiative is thrilled to announce that we graduated and placed 14 program participants from our second Navy Yard Workforce Development Initiatives training program today! These participants completed the three-week Shipyard Laborer Program in partnership with Philly Shipyard Inc. and 13 were extended a job offer for full-time permanent employment in the government and commercial shipbuilding industry starting at $14.00/hour. We partnered
As a historic, thriving waterfront district in Philadelphia, the Navy Yard is bustling with 15k people, 175 companies, and hundreds of career opportunities for all! Take a look at these 20 Navy Yard businesses that you could work for in 2020!
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it has entered into a lease agreement to build an approximately 136,000 square foot commercial-scale production facility at the Philadelphia Navy Yard for commercial and clinical production of autologous TIL products, including its candidate lifileucel.
On Saturday, March 23, the American Welding Society (AWS) and Rhoads Industries (Rhoads) hosted students from high schools across the five-county Philadelphia region to compete in a shielded metal arch weld (SMAW) competition at the Navy Yard.
